Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis |
|
By: Ingenuity Systems Posted: 2008-04-15 03:50:09 |
|
Ingenuity Systems, the leading provider of information solutions for life science researchers, and Pfizer Pharmaceuticals, Inc. (NYSE: PFE), the world's largest research-based biomedical and pharmaceutical company, announced a strategic partnership today. This new multi-year partnership promotes enterprise-wide deployment of IPA, enabling more researchers to use IPA for the exploration, interpretation, and analysis of life science information. In addition, Pfizer will integrate IPA and content from the Ingenuity knowledge base with other informatics solutions used throughout the Pfizer organization.
"We have selected Ingenuity as a partner to support our vision to implement an integrated and enterprise-scale pathway solution," stated Giles Day, Senior Director of the Targets and Mechanisms Informatics Group, Pfizer. "Through IPA, our internal scientists can access quality information to model and analyze complex biological and chemical systems and effectively share the information seamlessly across the organization. Our goal is to ensure our teams are selecting the best disease targets so that they will have higher confidence in the drug's mechanism of action and safety." "In addition to IPA, we have been able to offer a suite of powerful capabilities tailored specifically for Pfizer," stated Jake Leschly, CEO, Ingenuity Systems. "By integrating IPA with internal platforms, scientists are primed to unlock new insights from their data and internal information, and are more equipped to make faster, data-based decisions about targets. Multiple groups within Pfizer can now leverage IPA to rapidly make connections between pathways and their role in diseases, and then communicate results across the organization. We are very excited to be working with Pfizer on such a visionary program." About Ingenuity Pathways Analysis Ingenuity Pathways Analysis is an all-in-one software application that enables researchers to model, analyze, and understand the complex biological and chemical systems at the core of life science research. IPA's search capabilities provide users with access to the highest quality detail-rich knowledge available on genes, drugs, chemicals, protein families, cellular and disease processes, and signaling and metabolic pathways. IPA supports analysis of data from all experimental platforms, and is used at all stages of the drug discovery and development process, including target identification and validation, biomarker discovery, molecular toxicology, metabolomics, and pharmacogenomics. IPA has been broadly adopted and cited in hundreds of peer-reviewed journals. About Ingenuity Systems(R) Ingenuity Systems is a leading provider of information solutions for the exploration, interpretation, and analysis of life science information. All of Ingenuity's products and services have one common goal -- to help life science researchers generate maximum value from all types of biological and chemical knowledge. Ingenuity offers a broad and flexible range of solutions that can be tailored to needs of various clients, including academic and therapeutic area researchers, computational biologists and informatics departments, and suppliers in the life sciences industry. All of the products leverage Ingenuity's knowledge base, the largest data base of its kind, which houses the biological and chemical relationships extracted from scientific literature. The information is uniquely structured so scientists can ask complex biological questions to gain rapid insight into their experimental data or create relevant biological models to move forward in their research. Today, Ingenuity's solutions are used by thousands of researchers at hundreds of leading pharmaceutical, biotechnology, and academic research institutions worldwide. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, Australia, and Japan. http://www.ingenuity.com. |
| Trackback url: https://press.abc-directory.com/press/2864 |